Sugi Predict

Sugi Predict / Compounds / SCHEMBL178414

SCHEMBL178414

SCHEMBL178414

Cc1ccc(C(=O)NC2CC2)cc1N

nearest known ligand 0.60

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 11/20 0.60
▸ MAPT P10636 1/20 0.56
▸ TDP1 Q9NUW8 1/20 0.56
▸ SMYD3 Q9H7B4 4/20 0.54
▸ MAPK11 Q15759 4/20 0.52
▸ CYP2C9 P11712 2/20 0.52
▸ HSPB1 P04792 1/20 0.52
▸ NPC1 O15118 2/20 0.51
▸ RAB9A P51151 2/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ HPGD P15428 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ CYP3A4 P08684 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28078 0.98 MAPK14 (0.59) MAPK14MAPTTDP1SMYD3MAPK11
SCHEMBL9396679 0.92 NPC1 (0.63) MAPK14CYP2C9NPC1RAB9ACYP1A2
SCHEMBL3754370 0.87 MAPK14 (0.57) MAPK14SMYD3MAPK11CYP2C9HSPB1
SCHEMBL10282601 0.85 GLA (0.64) MAPK14MAPK11CYP2C9HSPB1NPC1
SCHEMBL31603829 0.85 SMYD3 (0.57) MAPK14MAPTSMYD3NPC1RAB9A
SCHEMBL24553421 0.83 HDAC4 (0.47) MAPK14MAPTTDP1MAPK11CYP2C9
SCHEMBL19175216 0.83 HDAC4 (0.47) MAPK14MAPTTDP1MAPK11CYP2C9
SCHEMBL8312180 0.82 MAPK14 (0.47) MAPK14MAPTTDP1SMYD3CYP2C9
SCHEMBL25548 0.82 MAPK14 (0.58) MAPK14SMYD3MAPK11CYP2C9HSPB1
SCHEMBL2948427 0.82 MAPK14 (0.58) MAPK14MAPK11CYP2C9HSPB1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190105311-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD Fulcrum Therapeutics, Inc. 2019-04-11 — — US disclosed
EP-1497019-B1 PYRROLO-TRIAZINE ANILINE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2015-05-20 — — EP disclosed
US-8742124-B2 Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors ASTRAZENECA AB (SE) 2014-06-03 — — US disclosed
US-8742124-B2 Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors ASTRAZENECA AB (SE) 2014-06-03 — — US disclosed
US-8742124-B2 Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors ASTRAZENECA AB (SE) 2014-06-03 — — US disclosed
EP-2468717-B1 Heterocyclic Amide Compounds Useful as Kinase Inhibitors BRISTOL MYERS SQUIBB CO (US) 2013-11-20 — — EP disclosed
US-8580838-B2 5-membered heterocycle-based p38 kinase inhibitors NOVARTIS AG (CH) 2013-11-12 — — US disclosed
US-8580838-B2 5-membered heterocycle-based p38 kinase inhibitors NOVARTIS AG (CH) 2013-11-12 — — US disclosed
US-20130172352-A1 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS NOVARTIS AG (CH) 2013-07-04 — — US disclosed
US-20130172352-A1 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS NOVARTIS AG (CH) 2013-07-04 — — US disclosed
WO-2005042537-A1 PHENYL-ANILINE SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-05-12 — — WO disclosed
US-20050049288-A1 5-MEMBERED HETEROCYCLE-BASED p38 KINASE INHIBITORS MEREO BIOPHARMA 1 LIMINTED (GB) 2005-03-03 — — US disclosed
WO-2005009973-A1 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS NOVARTIS AG (CH) 2005-02-03 — — WO disclosed
EP-1497019-A1 PYRROLO-TRIAZINE ANILINE COMPOUNDS USEFUL AS KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2005-01-19 — — EP disclosed
WO-2005000298-A2 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS NOVARTIS AG (CH) 2005-01-06 — — WO disclosed
US-20040254236-A1 P-38 inhibitors NOVARTIS AG (CH) 2004-12-16 — — US disclosed
WO-2004099156-A1 ARYL-SUBSTITUTED PYRAZOLE-AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-11-18 — — WO disclosed
US-20040082582-A1 Pyrrolo-triazine aniline compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-04-29 — — US disclosed
WO-2003090912-A9 PYRROLO-TRIAZINE ANILINE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2004-01-08 — — WO disclosed
WO-2003090912-A1 PYRROLO-TRIAZINE ANILINE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-11-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049288-A1 5-MEMBERED HETEROCYCLE-BASED p38 KINASE INHIBITORS MAPK1, MAP3K1, MAP3K8 MAPK14 33/4885MAPT 912/4885TDP1 1097/4885
US-20040082582-A1 Pyrrolo-triazine aniline compounds useful as kinase inhibitors RAF1, BRAF, MAP3K15 MAPK14 189/4885MAPT 2442/4885TDP1 904/4885
US-20040254236-A1 P-38 inhibitors MAPK8, MAP3K8, MAPK1 MAPK14 12/4885MAPT 817/4885TDP1 732/4885
US-20190105311-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD ZFX, TBL1XR1, TRIM28 MAPK14 196/4885MAPT 1537/4885TDP1 922/4885
US-20130172352-A1 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS MAPK1, MAP3K1, MAP3K8 MAPK14 33/4885MAPT 902/4885TDP1 1070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.